Free Trial

Pulmonx Corporation (NASDAQ:LUNG) Given Average Rating of "Moderate Buy" by Brokerages

Pulmonx logo with Medical background

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $11.53.

A number of research analysts have commented on the company. Citigroup decreased their price objective on Pulmonx from $6.50 to $4.15 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Canaccord Genuity Group cut their target price on Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. D. Boral Capital reiterated a "buy" rating and set a $17.00 target price on shares of Pulmonx in a research report on Thursday, May 1st. Finally, Piper Sandler reiterated an "overweight" rating and set a $9.00 target price (down from $10.00) on shares of Pulmonx in a research report on Thursday, May 1st.

Read Our Latest Stock Report on LUNG

Insider Activity

In other news, CFO Mehul Joshi sold 8,061 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $3.13, for a total transaction of $25,230.93. Following the completion of the sale, the chief financial officer directly owned 213,925 shares in the company, valued at approximately $669,585.25. This represents a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Steven S. Williamson sold 9,923 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $3.13, for a total value of $31,058.99. Following the sale, the chief executive officer owned 366,115 shares of the company's stock, valued at approximately $1,145,939.95. The trade was a 2.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,388 shares of company stock worth $136,044. 6.80% of the stock is owned by insiders.

Institutional Trading of Pulmonx

Several institutional investors and hedge funds have recently modified their holdings of LUNG. Deerfield Management Company L.P. Series C bought a new stake in shares of Pulmonx during the 4th quarter worth $10,421,000. Parkman Healthcare Partners LLC lifted its position in shares of Pulmonx by 194.4% during the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company's stock worth $4,118,000 after buying an additional 404,022 shares during the last quarter. Altium Capital Management LLC lifted its position in shares of Pulmonx by 63.0% during the 4th quarter. Altium Capital Management LLC now owns 815,000 shares of the company's stock worth $5,534,000 after buying an additional 315,000 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in shares of Pulmonx during the 1st quarter worth $2,041,000. Finally, Nuveen LLC bought a new stake in shares of Pulmonx during the 1st quarter worth $1,336,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Price Performance

NASDAQ LUNG remained flat at $2.73 on Friday. The company's stock had a trading volume of 220,591 shares, compared to its average volume of 305,718. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.29 and a current ratio of 4.97. The stock's fifty day moving average is $3.09 and its two-hundred day moving average is $5.39. Pulmonx has a 52-week low of $2.50 and a 52-week high of $9.37. The stock has a market capitalization of $109.91 million, a P/E ratio of -1.90 and a beta of 0.45.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. Pulmonx had a negative return on equity of 63.69% and a negative net margin of 65.27%. The firm had revenue of $22.54 million for the quarter, compared to analyst estimates of $22.03 million. Research analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

About Pulmonx

(Get Free Report

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Read More

Analyst Recommendations for Pulmonx (NASDAQ:LUNG)

Should You Invest $1,000 in Pulmonx Right Now?

Before you consider Pulmonx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.

While Pulmonx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines